Join us at the Dermatology Innovation Leadership Think Tank meeting featuring Christoph Ellebrecht, MD and Aimee Payne, MD, PhD, of University of Pennsylvania, as they discuss Chimeric antigen receptor (CAR) T cells as a precision curative therapy for gamma-delta T cell cancers.
The University of Pennsylvania’s successes in treating cancer with CAR T cell therapy represent two decades of investment in the people and infrastructure to advance these novel cellular immunotherapies to clinical trials. Clinician-scientists of all disciplines and in every career stage are now empowered to harness the immune system to treat more cancers, as well as other immune diseases.
• Understand how chimeric antigen receptor technology harnesses the immune system’s power to induce lasting remissions of previously refractory B cell leukemias and lymphomas
• See how breakthrough discoveries in B cell-mediated cancers have led to innovative approaches for B cell-mediated autoimmune diseases that may offer similar potential for lasting remission
• Learn how novel CAR technologies can provide opportunity to impactfully treat and potentially cure a breadth of gamma-delta T cell leukemias and lymphomas.
Who Should Attend?
• Biopharmaceutical Companies
• Government Officials & Regulators
• Patient Advocacy Organizations